^
Association details:
| Biomarker: | NRG1 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | zenocutuzumab (MCLA-128) (HER2 inhibitor, HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Excerpt:
...- Patient with advanced metastatic solid tumor with documented NRG1 fusion determined in a qualified local laboratory by molecular profiling using methods such as next generation sequencing [DNA or RNA] or FISH as routinely performed at CLIA or other similarly-certified laboratories....
Trial ID:
Source:
Title:
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
Published date:
05/26/2022
Excerpt:
Among the 71 pts with measurable disease, the INV-assessed confirmed ORR was 34% (90% CI, 25;44), including responses in NSCLC (35%; 14/40 pts), pancreas cancer (39%; 7/18 pts), breast cancer (2/4 pts), and cholangiocarcinoma (1/3 pts). Responses occurred at the first tumor assessment in 20/24 responders, and are ongoing in 13 pts....Zeno demonstrated robust and durable efficacy in pts with advanced NRG1+ cancer regardless of tumor histology.
DOI:
10.1200/JCO.2022.40.16_suppl.105
Trial ID:
